Featured Opening Session Speakers

NIAID Vaccine Research Center
BERNARD FIELDS LECTURE

United Nations Children’s Fund (former)
N'GALY-MANN LECTURE

Sexual Minorities Uganda (SMUG)
MARTIN DELANEY PRESENTATION

The 31st Conference on Retroviruses and Opportunistic Infections (CROI), held from March 3 to 6, 2024, is planned as an in-person conference at the Colorado Convention Center in Denver, Colorado. The best and most consequential original research on HIV and related conditions will define the science at the conference. CROI 2024 will also accept important new findings on SARS-CoV-2 and the mpox virus. The in-person conference will also feature innovative interactive sessions, rich poster sessions, and networking opportunities.

The CROI 2024 Program below is preliminary and subject to change. New information will be posted as it becomes available.

8:30 AM MT - 12:30 PM MT
New Investigator Workshop

Scott M. Hammer Workshop for New Investigators and Trainees 

Widely considered the most informative and comprehensive session, this workshop highlights key presentations that will take place during CROI. Although the workshop is directed toward new investigators and trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows), all CROI attendees are encouraged to attend. Scholarship recipients are required to attend.

Moderators: Katharine J. Bar, Hospital of the University of Pennsylvania (Philadelphia, PA, USA), and Serena S. Spudich, Yale University (New Haven, CT, USA)
    • The Evolving HIV Landscape: From the Unimaginable to the Imaginable Cure
      Adam Castillejo, London Patient (London, United Kingdom)
    • Navigating Presentations in Molecular Virology at CROI 2024
      Frank Kirchhoff, Ulm University Medical Center (Ulm, Germany)
    • Navigating Presentations in SARS-CoV-2 and HIV Immunology
      Elizabeth Connick, University of Arizona (Tucson, AZ, USA)
    • Navigating Presentations in HIV Cure at CROI 2024
      Afam A. Okoye, Oregon Health and Sciences University (Portland, OR, USA)
    • Navigating Presentations in Prevention at CROI 2024
      LaRon Nelson, Yale University (New Haven, CT, USA)
    • Navigating Presentations in Pediatric HIV at CROI 2024
      Jennifer Jao, Northwestern University (Chicago, IL, USA)
    • From Early-Stage Investigator to Change Agent: Thoughts on Maximizing the Impact of Your Career
      Jeanne Marrazzo, National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA)
1:30 PM MT - 3:30 PM MT
CONCURRENT TECHNICAL WORKSHOPS

Frontiers in Laboratory Technologies

Moderators: Katharine J. Bar, University of Pennsylvania (Philadelphia, PA, USA), and Frank Kirchhoff, Ulm University Medical Center (Ulm, Germany)
  • Cryoelectron Microscopy-Based Polyclonal Epitope Mapping (cryoEMPEM)
    Gabriel Ozorowski, The Scripps Research Institute (La Jolla, CA, USA)
  • A Spotlight on HIV: Visualizing Post-Entry Events by Correlative Light and Electron Microscopy
    Barbara Müller, Heidelberg University (Heidelberg, Germany)  
  • Single-Virus Tracking: Capturing Fast, 3-Dimensional Viral Dynamics in Live Tissue Models
    Kevin Welsher, Duke University (Durham, NC, USA)
  • Single-Cell Multi-Omics of HIV Cellular Reservoirs
    Iain Clark, University of California Berkeley (Berkeley, CA, USA)

Case-Based Workshop on the Liver and its Complications

Moderators: David L. Wyles, Denver Health Medical Center (Denver, CO, USA), and Annie Luetkemeyer, University of California San Francisco (San Francisco, CA, USA)
  • Steatotic Liver Disease in Persons with HIV
    Jennifer Price, University of California San Francisco (San Francisco, CA, USA)
  • Hepatitis Delta: What to Know, What to Do?
    Kathrin van Bremen, University of Bonn (Bonn, Germany)
  • Cirrhosis Management
    Mazen Noureddin, Houston Methodist Hospital (Houston, TX, USA)

Case-Based Workshop on Antiretroviral Therapy: A Panel Discussion*
*new this year

Moderators and Case Presenters: Claudia P. Cortes, University of Chile (Santiago, Chile) and Rajesh T. Gandhi, Massachusetts General Hospital (Boston, MA, USA)
  • Panel Discussion of Cases
    Anchalee Avihingsanon, HIV-NAT (Bangkok, Thailand)
    Cissy Kityo, Joint Clinical Research Centre (Kampala, Uganda)
    Anton Pozniak, Chelsea and Westminster Hospital (London, UK)
    Janine Trevillyan, Doherty Institute for Infection and Immunity (Melbourne, Australia)

Clinical Trial Design and Analysis

Moderators: Susan P. Buchbinder, San Francisco Department of Public Health (SanFrancisco, CA, USA), and Richard E. Chaisson, The Johns Hopkins University School of Medicine (Baltimore, MD, USA)
  • Exploring Strategies to Measure and Understand Users’ Preferences in HIV Prevention and Care
    José A. Bauermeister, University of Pennsylvania (Philadelphia, PA, USA)
  • Hybrid Effectiveness Implementation Studies: Unrecognized Challenges and Emerging Directions
    Elvin H. Geng, Washington University in St Louis (St Louis, MO, USA)
  • Stopping Clinical Trials Early: When and Why
    Sally Hunsberger, National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA)
5:00 PM MT - 7:00 PM MT
Opening Session

Welcome from the Chairs

Introduction of the Bernard Fields Lecture

Bernard Fields Lecture: Modern Vaccinology: A Legacy of HIV Research

Barney Graham, NIAID Vaccine Research Center (Bethesda, Maryland, USA)

The Bernard Fields Lecture recognizes a basic scientist for important and relevant contributions to the fields of virology and viral pathogenesis.

Introduction of the N’Galy-Mann Lecture

N’Galy-Mann Lecture: Reflections on Ending Pediatric HIV: Back to Basics, Confront the Unexpected, Challenge Assumptions

Dorothy M’bori-Ngacha, Formerly with United Nations Children’s Fund (Nairobi, Kenya)

The N’Galy-Mann Lecture recognizes an HIV/AIDS researcher for important and relevant work in the fields of epidemiology or clinical research.

Introduction of the Martin Delaney Presentation

Martin Delaney: Unveiling the Power of Uganda’s LGBTIQ Advocacy in Shaping HIV Response and Health Care Access

Frank Mugisha, Sexual Minorities Uganda (SMUG) (Kampala, Uganda)

The Martin Delaney Presentation recognizes the important work of community advocacy and engagement in research.

Conclusion of Opening Session and Welcome to Opening Reception

8:30 AM MT - 9:30 AM MT
MONDAY PLENARY SESSION

What’s New in HIV Vaccines: Vaccine-Induced Immune Responses
Juliana M. McElrathFred Hutchinson Cancer Center (Seattle, WA, USA)

Shall We Reach Human Papillomavirus Elimination in the Face of Inequity?
Nelly Mugo, Kenya Medical Research Institute (Nairobi, Kenya)

10:00 AM MT - 12:00 PM MT
CONCURRENT ORAL ABSTRACT SESSIONS

Oral Abstract Sessions include leading-edge research in HIV, hepatitis viruses, SARS-CoV-2, and other viral infections and their related conditions. During these 2-hour sessions, speakers present their peer-reviewed research on a specific topic area and respond to questions from attendees in 1 of 2 question and answer periods moderated by experts in the field.

  • HIV Immunology and Vaccines
  • Neuropathogenesis of HIV
  • Clinical Trials of Novel Antiretroviral Therapies
  • Game Changers in Prevention of HIV and Sexually Transmitted Infections
12:00 PM MT - 1:30 PM MT
Lunch Break for Attendees and Scholarship Meet the Luminary Sessions
1:30 PM MT - 2:30 PM MT
CONCURRENT THEMED DISCUSSIONS

Themed Discussions include up to 5 select poster abstracts connected by a theme. A discussant provides a 5-minute introduction outlining the state of the topic field, and then each presenter gives a brief overview of their Poster Abstract in 5 minutes using 5 slides (recommended) to summarize the noteworthy results, conclusions, and discussion points. Discussants interact with audience members and presenters to create a discussion that synthesizes the relevant information, covers key points of agreement and controversy, and draws comparisons to related work in the scientific field. At the conclusion of a Themed Discussion, the discussant provides a 5-minute summation highlighting the key information of the Poster Abstracts discussed and posing important questions for future research.

  • Viral Rebound
  • Is the Weight Over: GLP-1 Agonists Are Here
  • PEP Prevention Toolbox: Do We Know How to Use It?
  • Hazards Ahead: The Intersection of HIV and Substance Use
2:30 PM MT - 4:00 PM MT
POSTER SESSIONS

Poster Abstract Sessions comprise the majority of scientific information presented at CROI. Presenters of Poster Abstracts who attend CROI in person will be assigned to stand at their respective boards, organized by topic, on one of the 3 conference days. All posters will be available for viewing throughout the conference in the poster hall and in an electronic format on the CROI website and other electronic means (access is restricted to registered CROI attendees during the conference).

4:00 PM MT - 5:30 PM MT
CONCURRENT INTERACTIVE SESSIONS AND SYMPOSIA

The HIV Vaccine Journey: Don’t Stop Believin’  

Moderators: Georgia D. Tomaras, Duke University (Durham, NC, USA), and Leonidas Stamatatos, Fred Hutchison Cancer Center (Seattle, WA, USA)
  • Neutralizing Antibody Protection: Where Do We Go From Here?
    Yunda Huang, Fred Hutchison Cancer Center (Seattle, WA, USA)
  • Germline Targeting Strategies to Get On the Road Again
    Rogier W. Sanders, Academic Medical Center (Amsterdam, Netherlands)
  • Novel Immunization Strategies to Move on Down the Road
    Darrell Irvine, Massachusetts Institute of Technology (Cambridge, MA, USA)

Living Into Young Adulthood with Perinatal HIV

Moderators: Allison Agwu, Johns Hopkins University (Baltimore, MD, USA), and Victor Reyes, Howard University (Washington, DC, USA)
  • Epidemiology of Perinatally Acquired HIV Among Adolescents and Young Adults
    Mutsawashe Bwakura-Dangarembizi, University of Zimbabwe (Harare, Zimbabwe)
  • Historic Evolution of HIV and Mental Well-Being Among Adults Living With Perinatally Acquired HIV
    Ezer Kang, Howard University (Washington, DC, USA)
  • Cardiometabolic Risks and Complications: Adolescents and Young Adults with Perinatally Acquired HIV
    Sahera Dirajlal-Fargo, Ann & Robert H Lurie Children’s Hospital of Chicago (Chicago, IL, USA)

The Return of Syphilis

Moderators: Jodie Dionne, University of Alabama at Birmingham (Birmingham, AL, USA), and Alex de Voux, University of Cape Town (Cape Town, South Africa)
  • Why Can’t We Do Better at Diagnosing Syphilis?
    Ina Park, University of California San Francisco (San Francisco, CA, USA)
  • The Burgeoning Epidemic of Congenital Syphilis
    Angelica Espinosa Miranda, Ministry of Health (Brasilia, Brazil)
  • Syphilis Management Conundrums
    Khalil G. Ghanem, The Johns Hopkins University School of Medicine (Baltimore, MD, USA)
4:00 PM MT - 5:45 PM MT
ORAL SESSION: COVID-19: Epidemiologic and Clinical Insights
8:30 AM MT - 9:30 AM MT
TUESDAY PLENARY SESSION

HIV Assembly, Maturation Inhibitors, and Drug Resistance
Eric Freed, National Institutes of Health (Bethesda, MD, USA)

Accelerating Tuberculosis Elimination: Short-Course Prevention and Treatment
Vidya MaveByramjee Jeejeebhoy Government Medical College (Pune, India)

10:00 AM MT - 12:00 PM MT
CONCURRENT ORAL ABSTRACT SESSIONS

Oral Abstract Sessions include leading-edge research in HIV, hepatitis viruses, SARS-CoV-2, and other viral infections and their related conditions. During these 2-hour sessions, speakers present their peer-reviewed research on a specific topic area and respond to questions from attendees in 1 of 2 question and answer periods moderated by experts in the field.

  • Virus at the Wheel: Regulation of Replication and Immunity
  • Combating Complications of HIV
  • Hepatitis and Tuberculosis
  • Leaning Into the Success of Biomedical HIV Prevention
12:00 PM MT - 1:30 PM MT
Lunch Break for Attendees and Scholarship Meet the Luminary Sessions
1:30 PM MT - 2:30 PM MT
CONCURRENT THEMED DISCUSSIONS

Themed Discussions include up to 5 select poster abstracts connected by a theme. A discussant provides a 5-minute introduction outlining the state of the topic field, and then each presenter gives a brief overview of their Poster Abstract in 5 minutes using 5 slides (recommended) to summarize the noteworthy results, conclusions, and discussion points. Discussants interact with audience members and presenters to create a discussion that synthesizes the relevant information, covers key points of agreement and controversy, and draws comparisons to related work in the scientific field. At the conclusion of a Themed Discussion, the discussant provides a 5-minute summation highlighting the key information of the Poster Abstracts discussed and posing important questions for future research.

  • Persistent Immune Activation and Inflammation During Antiretroviral Therapy
  • Hypertension and HIV: Pregnancy, Postpartum, and Beyond
  • Anal Cancer Screening and Pathogenesis
  • Violence, Displacement, and HIV
2:30 PM MT - 4:00 PM MT
POSTER SESSIONS

Poster Abstract Sessions comprise the majority of scientific information presented at CROI. Presenters of Poster Abstracts who attend CROI in person will be assigned to stand at their respective boards, organized by topic, on one of the 3 conference days. All posters will be available for viewing throughout the conference in the poster hall and in an electronic format on the CROI website and other electronic means (access is restricted to registered CROI attendees during the conference).

4:00 PM MT - 5:30 PM MT
CONCURRENT INTERACTIVE SESSIONS AND SYMPOSIA

Not Just a Pretty Shape: HIV Assembly to Disassembly   

Moderators: Owen Pornillos, University of Virginia (Charlottesville, VA, USA), and Melissa Kane, University of Pittsburgh (Pittsburgh, PA, USA)
  • HIV-1 Genome Packaging During Virion Assembly: Selecting the Right RNA
    Wei-Shau Hu, National Cancer Institute (Frederick, MD, USA)
  • Virion Maturation: Folding Into the Right Shape
    Mamuka Kvaratskhelia, University of Colorado (Aurora, CO, USA)
  • Virion Disassembly: Keeping it Together Until the Right Moment
    Gregory Towers, University College London (London, UK)

New Frontiers in Hepatitis B  

Moderators: Gilles Wandeler, University of Bern (Bern, Switzerland), and Gail Matthews, Kirby Institute (Sydney, Australia)
  • Novel Markers of Hepatitis B: Clinical Utility for New Treatment Strategies
    Fabien Zoulim, L’Université Claude Bernard Lyon 1 (Lyon, France)
  • Advances in HBV Immunotherapy: The Beginning of the End?
    Adam Gehring, University of Toronto (Toronto, Canada)
  • How New WHO Guidance Can Transform Hepatitis B in Sub-Saharan Africa
    Olufunmilayo Lesi, World Health Organization (Geneva, Switzerland)
  • International Perspectives on Hepatitis B: Panel Discussion
    David L. Thomas, The Johns Hopkins University School of Medicine (Baltimore, MD, USA)
    Anna S. Lok, University of Michigan (Ann Arbor, MI, USA)
    Fabien Zoulim, L’Université Claude Bernard Lyon 1 (Lyon, France)
    Chien-Ching Hung, National Taiwan University Hospital (Taiwan City, Taiwan)
    Beatriz Grinsztejn, Oswaldo Cruz Foundation – Fiocruz (Rio de Janeiro, Brazil)
    Olufunmilayo Lesi, World Health Organization (Geneva, Switzerland)
  • Lived Experience
    Wes Spurr, (Denver, CO, USA)

Roundtable on DoxyPEP: Ready or Not…   

Moderators: Kenneth Ngure, Kenya Medical Research Institute (Nairobi, Kenya) and Michael Traeger, Monash University (Melbourne, Australia)
  • Introduction to DoxyPEP: Understanding the Issues
    Chase Cannon, University of Washington (Seattle, WA, USA)
  • DoxyPEP: Should We Worry About Antimicrobial Resistance?
    Béatrice Berçot, University Paris Cité (Paris, France)
  • Implementation of DoxyPEP: Challenges and Opportunities
    Stephanie Cohen, San Francisco Department of Public Health (San Francisco, CA, USA)

Impact on HIV Care and Services Among Refugees, Displaced Persons, and Marginalized Populations 

Moderators: Wafaa El-Sadr, Columbia University (New York, NY, USA) and Carlos del Rio, Emory University (Atlanta, GA, USA)
  • Overview of the Global Displacement Crisis
    Mesfin T. Tessema, International Rescue Committee (New York, NY, USA)
  • Panelist Refl ections on the Global Displacement Crisis
  • Meeting the Needs of People Affected by HIV From Ukraine
    Milosz Parczewski, Pomeranian Medical University (Szczecin, Poland)
  • Protracted Consequences of Displacement: A Perspective from Latin America
    Omar M. SuedPan American Health Organization (Washington, DC, USA)
  • Lived Experience From Ukraine
    Yana Panfilova, Teenergizer (Kyiv, Ukraine)
  • Roundtable Discussion
    Wafaa El-Sadr, Columbia University (New York, NY, USA)
    Mesfin T. Tessema, International Rescue Committee (New York, NY, USA)

    Carlos del Rio, Emory University (Atlanta, GA, USA)
    Milosz Parczewski, Pomeranian Medical University (Szczecin, Poland)
    Yana Panfilova, Teenergizer (Kyiv, Ukraine)
    Omar M. Sued, Pan American Health Organization (Washington, DC, USA)
8:30 AM MT - 9:30 AM MT
WEDNESDAY PLENARY SESSION

The End of Oral? How Long-Acting Formulations Are Changing the Management of Infectious Diseases
Charles Flexner, The John Hopkins University (Baltimore, MD, USA)

Diagnostics 4.0: The Future of Diagnostics for HIV and Related Infections
Nitika Pai, McGill University (Montreal, Quebec, Canada)

10:00 AM MT - 12:00 PM MT
CONCURRENT ORAL ABSTRACT SESSIONS

Oral Abstract Sessions include leading-edge research in HIV, hepatitis viruses, SARS-CoV-2, and other viral infections and their related conditions. During these 2-hour sessions, speakers present their peer-reviewed research on a specific topic area and respond to questions from attendees in 1 of 2 question and answer periods moderated by experts in the field.

  • HIV Reservoir and Cure Strategies
  • HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents
  • Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19
  • Strengthening Testing, Treatment, and Prevention of HIV and STIs
12:00 PM MT - 1:30 PM MT
Special Session: Clinical Late-Breaking Oral Abstracts
1:30 PM MT - 2:30 PM MT
CONCURRENT THEMED DISCUSSIONS

Themed Discussions include up to 5 select poster abstracts connected by a theme. A discussant provides a 5-minute introduction outlining the state of the topic field, and then each presenter gives a brief overview of their Poster Abstract in 5 minutes using 5 slides (recommended) to summarize the noteworthy results, conclusions, and discussion points. Discussants interact with audience members and presenters to create a discussion that synthesizes the relevant information, covers key points of agreement and controversy, and draws comparisons to related work in the scientific field. At the conclusion of a Themed Discussion, the discussant provides a 5-minute summation highlighting the key information of the Poster Abstracts discussed and posing important questions for future research.

  • Mucosal Immunity to HIV
  • Strategies for an HIV Cure
  • Dolutegravir Resistance in Resource-Limited Settings
  • Novel Interventions in HIV Programming
2:30 PM MT - 4:00 PM MT
POSTER SESSIONS

Poster Abstract Sessions comprise the majority of scientific information presented at CROI. Presenters of Poster Abstracts who attend CROI in person will be assigned to stand at their respective boards, organized by topic, on one of the 3 conference days. All posters will be available for viewing throughout the conference in the poster hall and in an electronic format on the CROI website and other electronic means (access is restricted to registered CROI attendees during the conference).

4:00 PM MT - 5:30 PM MT
CONCURRENT INTERACTIVE SESSIONS AND SYMPOSIA

Innovations in Intervention: Toward an HIV Cure

Moderator: Maria Buzón, Vall d’Hebron Research Institute (Barcelona, Spain) and Alberto Bosque, George Washington University (Washington, DC, USA)
  • From Mechanisms to Therapeutics: Eliminating HIV-Infected Cells by the CARD8 Inflammasome
    Liang Shan, Washington University in St Louis (St Louis, MO, USA)
  • From Mechanisms to Therapeutics: TACK Molecules Kill HIV-Infected Cells Through Inflammasome Activation
    Tracy L Diamond, Merck & Co, Inc (West Point, PA, USA)
  • From Transcriptomics to Therapeutics: A Host Restriction Factor That Targets HIV Expression
    Rasmi Thomas, Walter Reed Army Institute of Research (Silver Spring, MD,USA)
  • From Structure to Therapeutics: CD4 Mimetics “Open” Env and Sensitize HIV-1-Infected Cells to ADCC
    Andrés Finzi, Université de Montréal (Montreal, Canada)

Follow Your Heart: Managing Cardiovascular Disease Risk in PWH

Moderators: Matthew J Feinstein, Northwestern University (Chicago, IL, USA), and Franck Boccara (Sorbonne Universite, Paris, France)
  • Overview of the REPRIEVE Trial
    Steven K. Grinspoon, Massachusetts General Hospital (Boston, MA, USA)
  • Sex Differences in Atherosclerotic CVD Risks and Mechanisms: Insights From REPRIEVE
    Markella Zanni
    , Massachusetts General Hospital (Boston, MA, USA)
  • Immunomodulation and Cardiovascular Disease: Lessons Learned From HIV
    Priscilla Y. Hsue, University of California San Francisco (San Francisco, CA, USA)
  • Implications for Implementing CVD Risk Prevention Strategies for Lower- and Middle-Income Countries
    Mpiko Ntsekhe, University of Cape Town (Cape Town, South Africa)

Promise and Pitfalls of Biomedical Prevention: Beyond Phase III

Moderators: Linda-Gail Bekker, Desmond Tutu HIV Foundation (Cape Town, South Africa), and Bruno Spire, Institut National de la Santé et de la Recherche Médicale (Marseille, France)
  • Why is Cabotegravir Rollout So Slow?
    Rupa Patel, Centers for Disease Control and Prevention (Atlanta, GA, USA)
  • The Ring Comes Full Circle: Navigating the Complex Landscape of Biomedical Prevention Post-Phase III
    Leila E. Mansoor, Centre for the AIDS Programme of Research in South Africa (Durban, South Africa)
  • Challenging the Dogma of Event-Driven PrEP
    Jenell Stewart, Hennepin Healthcare Research Institute (Minneapolis, MN, USA)
Sunday, March 3, 2024
8:30 AM MT - 12:30 PM MT
New Investigator Workshop

Scott M. Hammer Workshop for New Investigators and Trainees 

Widely considered the most informative and comprehensive session, this workshop highlights key presentations that will take place during CROI. Although the workshop is directed toward new investigators and trainees (eg, undergraduate students, graduate students, postdoctoral fellows, and physician fellows), all CROI attendees are encouraged to attend. Scholarship recipients are required to attend.

Moderators: Katharine J. Bar, Hospital of the University of Pennsylvania (Philadelphia, PA, USA), and Serena S. Spudich, Yale University (New Haven, CT, USA)
    • The Evolving HIV Landscape: From the Unimaginable to the Imaginable Cure
      Adam Castillejo, London Patient (London, United Kingdom)
    • Navigating Presentations in Molecular Virology at CROI 2024
      Frank Kirchhoff, Ulm University Medical Center (Ulm, Germany)
    • Navigating Presentations in SARS-CoV-2 and HIV Immunology
      Elizabeth Connick, University of Arizona (Tucson, AZ, USA)
    • Navigating Presentations in HIV Cure at CROI 2024
      Afam A. Okoye, Oregon Health and Sciences University (Portland, OR, USA)
    • Navigating Presentations in Prevention at CROI 2024
      LaRon Nelson, Yale University (New Haven, CT, USA)
    • Navigating Presentations in Pediatric HIV at CROI 2024
      Jennifer Jao, Northwestern University (Chicago, IL, USA)
    • From Early-Stage Investigator to Change Agent: Thoughts on Maximizing the Impact of Your Career
      Jeanne Marrazzo, National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA)
1:30 PM MT - 3:30 PM MT
CONCURRENT TECHNICAL WORKSHOPS

Frontiers in Laboratory Technologies

Moderators: Katharine J. Bar, University of Pennsylvania (Philadelphia, PA, USA), and Frank Kirchhoff, Ulm University Medical Center (Ulm, Germany)
  • Cryoelectron Microscopy-Based Polyclonal Epitope Mapping (cryoEMPEM)
    Gabriel Ozorowski, The Scripps Research Institute (La Jolla, CA, USA)
  • A Spotlight on HIV: Visualizing Post-Entry Events by Correlative Light and Electron Microscopy
    Barbara Müller, Heidelberg University (Heidelberg, Germany)  
  • Single-Virus Tracking: Capturing Fast, 3-Dimensional Viral Dynamics in Live Tissue Models
    Kevin Welsher, Duke University (Durham, NC, USA)
  • Single-Cell Multi-Omics of HIV Cellular Reservoirs
    Iain Clark, University of California Berkeley (Berkeley, CA, USA)

Case-Based Workshop on the Liver and its Complications

Moderators: David L. Wyles, Denver Health Medical Center (Denver, CO, USA), and Annie Luetkemeyer, University of California San Francisco (San Francisco, CA, USA)
  • Steatotic Liver Disease in Persons with HIV
    Jennifer Price, University of California San Francisco (San Francisco, CA, USA)
  • Hepatitis Delta: What to Know, What to Do?
    Kathrin van Bremen, University of Bonn (Bonn, Germany)
  • Cirrhosis Management
    Mazen Noureddin, Houston Methodist Hospital (Houston, TX, USA)

Case-Based Workshop on Antiretroviral Therapy: A Panel Discussion*
*new this year

Moderators and Case Presenters: Claudia P. Cortes, University of Chile (Santiago, Chile) and Rajesh T. Gandhi, Massachusetts General Hospital (Boston, MA, USA)
  • Panel Discussion of Cases
    Anchalee Avihingsanon, HIV-NAT (Bangkok, Thailand)
    Cissy Kityo, Joint Clinical Research Centre (Kampala, Uganda)
    Anton Pozniak, Chelsea and Westminster Hospital (London, UK)
    Janine Trevillyan, Doherty Institute for Infection and Immunity (Melbourne, Australia)

Clinical Trial Design and Analysis

Moderators: Susan P. Buchbinder, San Francisco Department of Public Health (SanFrancisco, CA, USA), and Richard E. Chaisson, The Johns Hopkins University School of Medicine (Baltimore, MD, USA)
  • Exploring Strategies to Measure and Understand Users’ Preferences in HIV Prevention and Care
    José A. Bauermeister, University of Pennsylvania (Philadelphia, PA, USA)
  • Hybrid Effectiveness Implementation Studies: Unrecognized Challenges and Emerging Directions
    Elvin H. Geng, Washington University in St Louis (St Louis, MO, USA)
  • Stopping Clinical Trials Early: When and Why
    Sally Hunsberger, National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA)
5:00 PM MT - 7:00 PM MT
Opening Session

Welcome from the Chairs

Introduction of the Bernard Fields Lecture

Bernard Fields Lecture: Modern Vaccinology: A Legacy of HIV Research

Barney Graham, NIAID Vaccine Research Center (Bethesda, Maryland, USA)

The Bernard Fields Lecture recognizes a basic scientist for important and relevant contributions to the fields of virology and viral pathogenesis.

Introduction of the N’Galy-Mann Lecture

N’Galy-Mann Lecture: Reflections on Ending Pediatric HIV: Back to Basics, Confront the Unexpected, Challenge Assumptions

Dorothy M’bori-Ngacha, Formerly with United Nations Children’s Fund (Nairobi, Kenya)

The N’Galy-Mann Lecture recognizes an HIV/AIDS researcher for important and relevant work in the fields of epidemiology or clinical research.

Introduction of the Martin Delaney Presentation

Martin Delaney: Unveiling the Power of Uganda’s LGBTIQ Advocacy in Shaping HIV Response and Health Care Access

Frank Mugisha, Sexual Minorities Uganda (SMUG) (Kampala, Uganda)

The Martin Delaney Presentation recognizes the important work of community advocacy and engagement in research.

Conclusion of Opening Session and Welcome to Opening Reception

Monday, March 4, 2024
8:30 AM MT - 9:30 AM MT
MONDAY PLENARY SESSION

What’s New in HIV Vaccines: Vaccine-Induced Immune Responses
Juliana M. McElrathFred Hutchinson Cancer Center (Seattle, WA, USA)

Shall We Reach Human Papillomavirus Elimination in the Face of Inequity?
Nelly Mugo, Kenya Medical Research Institute (Nairobi, Kenya)

10:00 AM MT - 12:00 PM MT
CONCURRENT ORAL ABSTRACT SESSIONS

Oral Abstract Sessions include leading-edge research in HIV, hepatitis viruses, SARS-CoV-2, and other viral infections and their related conditions. During these 2-hour sessions, speakers present their peer-reviewed research on a specific topic area and respond to questions from attendees in 1 of 2 question and answer periods moderated by experts in the field.

  • HIV Immunology and Vaccines
  • Neuropathogenesis of HIV
  • Clinical Trials of Novel Antiretroviral Therapies
  • Game Changers in Prevention of HIV and Sexually Transmitted Infections
12:00 PM MT - 1:30 PM MT
Lunch Break for Attendees and Scholarship Meet the Luminary Sessions
1:30 PM MT - 2:30 PM MT
CONCURRENT THEMED DISCUSSIONS

Themed Discussions include up to 5 select poster abstracts connected by a theme. A discussant provides a 5-minute introduction outlining the state of the topic field, and then each presenter gives a brief overview of their Poster Abstract in 5 minutes using 5 slides (recommended) to summarize the noteworthy results, conclusions, and discussion points. Discussants interact with audience members and presenters to create a discussion that synthesizes the relevant information, covers key points of agreement and controversy, and draws comparisons to related work in the scientific field. At the conclusion of a Themed Discussion, the discussant provides a 5-minute summation highlighting the key information of the Poster Abstracts discussed and posing important questions for future research.

  • Viral Rebound
  • Is the Weight Over: GLP-1 Agonists Are Here
  • PEP Prevention Toolbox: Do We Know How to Use It?
  • Hazards Ahead: The Intersection of HIV and Substance Use
2:30 PM MT - 4:00 PM MT
POSTER SESSIONS

Poster Abstract Sessions comprise the majority of scientific information presented at CROI. Presenters of Poster Abstracts who attend CROI in person will be assigned to stand at their respective boards, organized by topic, on one of the 3 conference days. All posters will be available for viewing throughout the conference in the poster hall and in an electronic format on the CROI website and other electronic means (access is restricted to registered CROI attendees during the conference).

4:00 PM MT - 5:30 PM MT
CONCURRENT INTERACTIVE SESSIONS AND SYMPOSIA

The HIV Vaccine Journey: Don’t Stop Believin’  

Moderators: Georgia D. Tomaras, Duke University (Durham, NC, USA), and Leonidas Stamatatos, Fred Hutchison Cancer Center (Seattle, WA, USA)
  • Neutralizing Antibody Protection: Where Do We Go From Here?
    Yunda Huang, Fred Hutchison Cancer Center (Seattle, WA, USA)
  • Germline Targeting Strategies to Get On the Road Again
    Rogier W. Sanders, Academic Medical Center (Amsterdam, Netherlands)
  • Novel Immunization Strategies to Move on Down the Road
    Darrell Irvine, Massachusetts Institute of Technology (Cambridge, MA, USA)

Living Into Young Adulthood with Perinatal HIV

Moderators: Allison Agwu, Johns Hopkins University (Baltimore, MD, USA), and Victor Reyes, Howard University (Washington, DC, USA)
  • Epidemiology of Perinatally Acquired HIV Among Adolescents and Young Adults
    Mutsawashe Bwakura-Dangarembizi, University of Zimbabwe (Harare, Zimbabwe)
  • Historic Evolution of HIV and Mental Well-Being Among Adults Living With Perinatally Acquired HIV
    Ezer Kang, Howard University (Washington, DC, USA)
  • Cardiometabolic Risks and Complications: Adolescents and Young Adults with Perinatally Acquired HIV
    Sahera Dirajlal-Fargo, Ann & Robert H Lurie Children’s Hospital of Chicago (Chicago, IL, USA)

The Return of Syphilis

Moderators: Jodie Dionne, University of Alabama at Birmingham (Birmingham, AL, USA), and Alex de Voux, University of Cape Town (Cape Town, South Africa)
  • Why Can’t We Do Better at Diagnosing Syphilis?
    Ina Park, University of California San Francisco (San Francisco, CA, USA)
  • The Burgeoning Epidemic of Congenital Syphilis
    Angelica Espinosa Miranda, Ministry of Health (Brasilia, Brazil)
  • Syphilis Management Conundrums
    Khalil G. Ghanem, The Johns Hopkins University School of Medicine (Baltimore, MD, USA)
4:00 PM MT - 5:45 PM MT
ORAL SESSION: COVID-19: Epidemiologic and Clinical Insights
Tuesday, March 5, 2024
8:30 AM MT - 9:30 AM MT
TUESDAY PLENARY SESSION

HIV Assembly, Maturation Inhibitors, and Drug Resistance
Eric Freed, National Institutes of Health (Bethesda, MD, USA)

Accelerating Tuberculosis Elimination: Short-Course Prevention and Treatment
Vidya MaveByramjee Jeejeebhoy Government Medical College (Pune, India)

10:00 AM MT - 12:00 PM MT
CONCURRENT ORAL ABSTRACT SESSIONS

Oral Abstract Sessions include leading-edge research in HIV, hepatitis viruses, SARS-CoV-2, and other viral infections and their related conditions. During these 2-hour sessions, speakers present their peer-reviewed research on a specific topic area and respond to questions from attendees in 1 of 2 question and answer periods moderated by experts in the field.

  • Virus at the Wheel: Regulation of Replication and Immunity
  • Combating Complications of HIV
  • Hepatitis and Tuberculosis
  • Leaning Into the Success of Biomedical HIV Prevention
12:00 PM MT - 1:30 PM MT
Lunch Break for Attendees and Scholarship Meet the Luminary Sessions
1:30 PM MT - 2:30 PM MT
CONCURRENT THEMED DISCUSSIONS

Themed Discussions include up to 5 select poster abstracts connected by a theme. A discussant provides a 5-minute introduction outlining the state of the topic field, and then each presenter gives a brief overview of their Poster Abstract in 5 minutes using 5 slides (recommended) to summarize the noteworthy results, conclusions, and discussion points. Discussants interact with audience members and presenters to create a discussion that synthesizes the relevant information, covers key points of agreement and controversy, and draws comparisons to related work in the scientific field. At the conclusion of a Themed Discussion, the discussant provides a 5-minute summation highlighting the key information of the Poster Abstracts discussed and posing important questions for future research.

  • Persistent Immune Activation and Inflammation During Antiretroviral Therapy
  • Hypertension and HIV: Pregnancy, Postpartum, and Beyond
  • Anal Cancer Screening and Pathogenesis
  • Violence, Displacement, and HIV
2:30 PM MT - 4:00 PM MT
POSTER SESSIONS

Poster Abstract Sessions comprise the majority of scientific information presented at CROI. Presenters of Poster Abstracts who attend CROI in person will be assigned to stand at their respective boards, organized by topic, on one of the 3 conference days. All posters will be available for viewing throughout the conference in the poster hall and in an electronic format on the CROI website and other electronic means (access is restricted to registered CROI attendees during the conference).

4:00 PM MT - 5:30 PM MT
CONCURRENT INTERACTIVE SESSIONS AND SYMPOSIA

Not Just a Pretty Shape: HIV Assembly to Disassembly   

Moderators: Owen Pornillos, University of Virginia (Charlottesville, VA, USA), and Melissa Kane, University of Pittsburgh (Pittsburgh, PA, USA)
  • HIV-1 Genome Packaging During Virion Assembly: Selecting the Right RNA
    Wei-Shau Hu, National Cancer Institute (Frederick, MD, USA)
  • Virion Maturation: Folding Into the Right Shape
    Mamuka Kvaratskhelia, University of Colorado (Aurora, CO, USA)
  • Virion Disassembly: Keeping it Together Until the Right Moment
    Gregory Towers, University College London (London, UK)

New Frontiers in Hepatitis B  

Moderators: Gilles Wandeler, University of Bern (Bern, Switzerland), and Gail Matthews, Kirby Institute (Sydney, Australia)
  • Novel Markers of Hepatitis B: Clinical Utility for New Treatment Strategies
    Fabien Zoulim, L’Université Claude Bernard Lyon 1 (Lyon, France)
  • Advances in HBV Immunotherapy: The Beginning of the End?
    Adam Gehring, University of Toronto (Toronto, Canada)
  • How New WHO Guidance Can Transform Hepatitis B in Sub-Saharan Africa
    Olufunmilayo Lesi, World Health Organization (Geneva, Switzerland)
  • International Perspectives on Hepatitis B: Panel Discussion
    David L. Thomas, The Johns Hopkins University School of Medicine (Baltimore, MD, USA)
    Anna S. Lok, University of Michigan (Ann Arbor, MI, USA)
    Fabien Zoulim, L’Université Claude Bernard Lyon 1 (Lyon, France)
    Chien-Ching Hung, National Taiwan University Hospital (Taiwan City, Taiwan)
    Beatriz Grinsztejn, Oswaldo Cruz Foundation – Fiocruz (Rio de Janeiro, Brazil)
    Olufunmilayo Lesi, World Health Organization (Geneva, Switzerland)
  • Lived Experience
    Wes Spurr, (Denver, CO, USA)

Roundtable on DoxyPEP: Ready or Not…   

Moderators: Kenneth Ngure, Kenya Medical Research Institute (Nairobi, Kenya) and Michael Traeger, Monash University (Melbourne, Australia)
  • Introduction to DoxyPEP: Understanding the Issues
    Chase Cannon, University of Washington (Seattle, WA, USA)
  • DoxyPEP: Should We Worry About Antimicrobial Resistance?
    Béatrice Berçot, University Paris Cité (Paris, France)
  • Implementation of DoxyPEP: Challenges and Opportunities
    Stephanie Cohen, San Francisco Department of Public Health (San Francisco, CA, USA)

Impact on HIV Care and Services Among Refugees, Displaced Persons, and Marginalized Populations 

Moderators: Wafaa El-Sadr, Columbia University (New York, NY, USA) and Carlos del Rio, Emory University (Atlanta, GA, USA)
  • Overview of the Global Displacement Crisis
    Mesfin T. Tessema, International Rescue Committee (New York, NY, USA)
  • Panelist Refl ections on the Global Displacement Crisis
  • Meeting the Needs of People Affected by HIV From Ukraine
    Milosz Parczewski, Pomeranian Medical University (Szczecin, Poland)
  • Protracted Consequences of Displacement: A Perspective from Latin America
    Omar M. SuedPan American Health Organization (Washington, DC, USA)
  • Lived Experience From Ukraine
    Yana Panfilova, Teenergizer (Kyiv, Ukraine)
  • Roundtable Discussion
    Wafaa El-Sadr, Columbia University (New York, NY, USA)
    Mesfin T. Tessema, International Rescue Committee (New York, NY, USA)

    Carlos del Rio, Emory University (Atlanta, GA, USA)
    Milosz Parczewski, Pomeranian Medical University (Szczecin, Poland)
    Yana Panfilova, Teenergizer (Kyiv, Ukraine)
    Omar M. Sued, Pan American Health Organization (Washington, DC, USA)
Wednesday, March 6, 2024
8:30 AM MT - 9:30 AM MT
WEDNESDAY PLENARY SESSION

The End of Oral? How Long-Acting Formulations Are Changing the Management of Infectious Diseases
Charles Flexner, The John Hopkins University (Baltimore, MD, USA)

Diagnostics 4.0: The Future of Diagnostics for HIV and Related Infections
Nitika Pai, McGill University (Montreal, Quebec, Canada)

10:00 AM MT - 12:00 PM MT
CONCURRENT ORAL ABSTRACT SESSIONS

Oral Abstract Sessions include leading-edge research in HIV, hepatitis viruses, SARS-CoV-2, and other viral infections and their related conditions. During these 2-hour sessions, speakers present their peer-reviewed research on a specific topic area and respond to questions from attendees in 1 of 2 question and answer periods moderated by experts in the field.

  • HIV Reservoir and Cure Strategies
  • HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents
  • Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19
  • Strengthening Testing, Treatment, and Prevention of HIV and STIs
12:00 PM MT - 1:30 PM MT
Special Session: Clinical Late-Breaking Oral Abstracts
1:30 PM MT - 2:30 PM MT
CONCURRENT THEMED DISCUSSIONS

Themed Discussions include up to 5 select poster abstracts connected by a theme. A discussant provides a 5-minute introduction outlining the state of the topic field, and then each presenter gives a brief overview of their Poster Abstract in 5 minutes using 5 slides (recommended) to summarize the noteworthy results, conclusions, and discussion points. Discussants interact with audience members and presenters to create a discussion that synthesizes the relevant information, covers key points of agreement and controversy, and draws comparisons to related work in the scientific field. At the conclusion of a Themed Discussion, the discussant provides a 5-minute summation highlighting the key information of the Poster Abstracts discussed and posing important questions for future research.

  • Mucosal Immunity to HIV
  • Strategies for an HIV Cure
  • Dolutegravir Resistance in Resource-Limited Settings
  • Novel Interventions in HIV Programming
2:30 PM MT - 4:00 PM MT
POSTER SESSIONS

Poster Abstract Sessions comprise the majority of scientific information presented at CROI. Presenters of Poster Abstracts who attend CROI in person will be assigned to stand at their respective boards, organized by topic, on one of the 3 conference days. All posters will be available for viewing throughout the conference in the poster hall and in an electronic format on the CROI website and other electronic means (access is restricted to registered CROI attendees during the conference).

4:00 PM MT - 5:30 PM MT
CONCURRENT INTERACTIVE SESSIONS AND SYMPOSIA

Innovations in Intervention: Toward an HIV Cure

Moderator: Maria Buzón, Vall d’Hebron Research Institute (Barcelona, Spain) and Alberto Bosque, George Washington University (Washington, DC, USA)
  • From Mechanisms to Therapeutics: Eliminating HIV-Infected Cells by the CARD8 Inflammasome
    Liang Shan, Washington University in St Louis (St Louis, MO, USA)
  • From Mechanisms to Therapeutics: TACK Molecules Kill HIV-Infected Cells Through Inflammasome Activation
    Tracy L Diamond, Merck & Co, Inc (West Point, PA, USA)
  • From Transcriptomics to Therapeutics: A Host Restriction Factor That Targets HIV Expression
    Rasmi Thomas, Walter Reed Army Institute of Research (Silver Spring, MD,USA)
  • From Structure to Therapeutics: CD4 Mimetics “Open” Env and Sensitize HIV-1-Infected Cells to ADCC
    Andrés Finzi, Université de Montréal (Montreal, Canada)

Follow Your Heart: Managing Cardiovascular Disease Risk in PWH

Moderators: Matthew J Feinstein, Northwestern University (Chicago, IL, USA), and Franck Boccara (Sorbonne Universite, Paris, France)
  • Overview of the REPRIEVE Trial
    Steven K. Grinspoon, Massachusetts General Hospital (Boston, MA, USA)
  • Sex Differences in Atherosclerotic CVD Risks and Mechanisms: Insights From REPRIEVE
    Markella Zanni
    , Massachusetts General Hospital (Boston, MA, USA)
  • Immunomodulation and Cardiovascular Disease: Lessons Learned From HIV
    Priscilla Y. Hsue, University of California San Francisco (San Francisco, CA, USA)
  • Implications for Implementing CVD Risk Prevention Strategies for Lower- and Middle-Income Countries
    Mpiko Ntsekhe, University of Cape Town (Cape Town, South Africa)

Promise and Pitfalls of Biomedical Prevention: Beyond Phase III

Moderators: Linda-Gail Bekker, Desmond Tutu HIV Foundation (Cape Town, South Africa), and Bruno Spire, Institut National de la Santé et de la Recherche Médicale (Marseille, France)
  • Why is Cabotegravir Rollout So Slow?
    Rupa Patel, Centers for Disease Control and Prevention (Atlanta, GA, USA)
  • The Ring Comes Full Circle: Navigating the Complex Landscape of Biomedical Prevention Post-Phase III
    Leila E. Mansoor, Centre for the AIDS Programme of Research in South Africa (Durban, South Africa)
  • Challenging the Dogma of Event-Driven PrEP
    Jenell Stewart, Hennepin Healthcare Research Institute (Minneapolis, MN, USA)

Last Modified: Feb 22, 2024 @ 4:25 pm